Withdrawn Posters

FEATURED CLINICAL POSTERS, C-003/POD51: TELEMEDICINE DELIVERED TOBACCO CESSION TREATMENT IN RURAL ALASKA NATIVE COMMUNITIES: A RANDOMIZED CONTROLLED TRIAL

CLINICAL POSTER SESSION, C-052: INTRODUCING A NOVEL BIORELEVANT IN VITRO DISSOLUTION METHOD FOR THE ASSESSMENT OF NICOTINE RELEASE FROM ORAL NICOTINE AND TOBACCO PRODUCTS

CLINICAL POSTER SESSION, C-028: PILOT CESSION TRIAL IN PATIENTS WITH SEVERE MENTAL ILLNESS

PUBLIC HEALTH POSTER SESSION, PH-301: ELECTRONIC CIGARETTE CONSUMER PREFERENCES AMONG YOUTH - A DISCRETE CHOICE EXPERIMENT

PUBLIC HEALTH POSTER SESSION, PH-046: IMPACT OF AGE AT SMOKING INITATION ON PREVALENCE OF MULTIPLE HEALTH BEHAVIORS AMONG U.S. ADULTS

PUBLIC HEALTH POSTER SESSION, PH-204: THE VAPING ROLLERCOASTER - DIGGING DEEPER INTO THE UPS AND DOWNS OF TEEN VAPE AND OTHER TOBACCO USE IN VIRGINIA

PUBLIC HEALTH POSTER SESSION, PH-028: AND THE KIDS VAPED ON: TEENS, TOBACCO, AND THE NYTS

PUBLIC HEALTH POSTER SESSION, PH-329: EXPLORING YOUNG ADULTS' PSYCHO-SOCIAL EXPERIENCES OF ENDS USE: A QUALITATIVE SYSTEMATIC REVIEW

PUBLIC HEALTH POSTER SESSION, PH-158: VAPE AND COVID-19 RISK PERCEPTIONS ON SOCIAL MEDIA AND REDDIT

PUBLIC HEALTH POSTER SESSION, PH-275: PREDICTORS OF RESIDENTIAL PROXIMITY TO TOBACCO RETAILERS IN PHILADELPHIA IN 2018

PUBLIC HEALTH POSTER SESSION, PH-043: HELPING YOUTH QUIT TOBACCO: STATE-OF-THE-SCIENCE AND INNOVATION

PUBLIC HEALTH POSTER SESSION, PH-344: DETERMINANTS OF PERCEIVED FACTORS DISCOURAGING ELECTRONIC NICOTINE DELIVERY SYSTEMS (ENDS) USE AMONG YOUTH


PUBLIC HEALTH POSTER SESSION, PH-065: TRANSITION BETWEEN SMOKING AND VAPING STATUSES IN YOUNG ADULTHOOD

PUBLIC HEALTH POSTER SESSION, P-030: TOBACCO FLAVOURING AND DESIGN FEATURES NEAR SCHOOLS BEFORE PLAIN PACKAGING IN URUGUAY

PUBLIC HEALTH POSTER SESSION, P-079: WE’VE SEEN THIS BEFORE - JUUL’S (BIG TOBACCO’S) PLAYBOOK

PUBLIC HEALTH POSTER SESSION, P-026: EVALUATION OF FLAVORED TOBACCO RESTRICTIONS IN MASSACHUSETTS: RESULTS AND LESSONS LEARNED

Withdrawn Spoken Presentations

Symposium

PAVING THE ROAD WITH THE BEST INTENTIONS STILL LEADS US HERE: (NEGATIVE) UNINTENDED CONSEQUENCES OF TOBACCO REGULATORY POLICIES ACROSS PRODUCTS AND POPULATIONS, SYM18E: UNINTENDED CONSEQUENCES OF TOBACCO CONTROL POLICIES IN LOW- AND MIDDLE-INCOME COUNTRIES: A CASE STUDY OF THE 100% SMOKE FREE LAW IN UGANDA

BIOMARKERS FOR TOBACCO DEPENDENCE AND TREATMENT: PROMISE AND PITFALLS, SYM11B: USING BIOMARKERS IN SMOKING CESSION TRIALS TO EXPLAIN DIFFERENTIAL TREATMENT RESPONSE

Podium

UNDERSTANDING NICOTINE DEPENDENCE AND SMOKING CESSION IN THE CONTEXT OF HIV, POD10-002: THE RELATIONSHIP BETWEEN PERCEIVED DISCRIMINATION AND NICOTINE DEPENDENCE IN A SAMPLE OF PEOPLE LIVING WITH HIV

BANNING MENTHOL IN CIGARETTES, POD30-004: USE OF TOBACCO PRODUCTS AND PASSIVE EXPOSURE TO THEM IN EUROPE, THE TACKSHS PROJECT
**New Presenting Author**

**PRE-CLINICAL POSTER SESSION, PC-022:** IN UTERO EXPOSURE TO THIRDHAND SMOKE MODULATES PLATELET FUNCTION AND INCREASES THE RISK OF THROMBOGENESIS  
Presenter changed to Ahmed Alarabi

**CLINICAL POSTER SESSION, C-040:** COMPARING VIDEO OBSERVATION TO ELECTRONIC TOPOGRAPHY DEVICE AS A METHOD FOR MEASURING CIGARETTE PUFFING BEHAVIOR  
Presenter changed to Joshua Karelitz

**CLINICAL POSTER SESSION, C-011:** TREATMENT FIDELITY IN BEHAVIORAL TOBACCO CESSATION TRIALS - SCOPING REVIEW AND MEASUREMENT RECOMMENDATIONS  
Presenter changed to Alana Rojewski

**CLINICAL POSTER SESSION, C-029:** REQUIRING COACHING AND NOT REQUIRING COACHING TO OBTAIN NICOTINE REPLACEMENT THERAPY (NRT) USING AN ONLINE APPLICATION THROUGH THE NEW YORK STATE SMOKERS QUITLINE (QL): A COMPARISON OF CONCURRENTLY APPLYING DIFFERENT ENROLLMENT CRITERIA FOR DIFFERENT NYS  
Presenter changed to Cheryl Rivard

**PUBLIC HEALTH POSTER SESSION, PH-138:** CHARACTERISTICS OF TOBACCO-RELATED TWEETS ORIGINATING FROM CALIFORNIA COLLEGE CAMPUSES FROM 2015-2019  
Presenter changed to Vidya Purushothaman

**PUBLIC HEALTH POSTER SESSION, PH-305:** ARE THERE GENERATIONAL DIFFERENCES IN PREDICTORS OF QUIT ATTEMPTS AND SMOKING ABSTINENCE. FINDINGS FROM THE 2016 AND 2018 ITC FOUR COUNTRY SMOKING AND VAPING SURVEYS  
Presenter changed to Ron Borland

**PUBLIC HEALTH POSTER SESSION, PH-324:** COMPLIANCE WITH THE SMOKE-FREE POLICY IN KARACHI, PAKISTAN  
Presenter changed to Ryan Kennedy

**PUBLIC HEALTH POSTER SESSION, PH-325:** E-LIQUID FLAVOUR CHOICES BY NEW ZEALAND ADULT SMOKERS USING AN ELECTRONIC NICOTINE DELIVERY SYSTEM: A LONGITUDINAL EXPLORATION OVER 12-20 WEEKS  
Presenter changed to Janet Hoek

**PUBLIC HEALTH POSTER SESSION, PH-142:** MESSAGE EFFECT SPREAD BEYOND TARGETED BELIEFS IN ENDS PREVENTION PRETESTING  
Presenter changed to Mario Navarro

**PUBLIC HEALTH POSTER SESSION, PH-143:** PERCEIVED AD EFFECTIVENESS COMPARING TWO MEASUREMENT APPROACHES IN ENDS PREVENTION MESSAGING  
Presenter changed to Mario Navarro

**PUBLIC HEALTH POSTER SESSION, PH-238:** ASSOCIATION OF BASELINE DAYTIME SLEEPINESS WITH OTHER PSYCHIATRIC CONDITIONS AND SMOKING CESSATION OUTCOMES AMONG CANCER PATIENTS  
Presenter changed to Christine Sheffer

**PUBLIC HEALTH POSTER SESSION, PH-150:** CHARACTERIZING CALIFORNIA LICENSURE STATUS AND TOBACCO USER EXPERIENCES WITH ADVERSE EVENTS USING BUSINESS LISTING PLATFORM YELP!  
Presenter changed to Tim Mackey

**PUBLIC HEALTH POSTER SESSION, PH-165:** CHARACTERIZING THE ADVERTISING STRATEGIES AND EXPENDITURES OF THE TRADITIONAL AND NOVEL SMOKELESS TOBACCO PRODUCTS PROMOTION  
Presenter changed to Anna Kostygina

**PUBLIC HEALTH POSTER SESSION, PH-343:** USING TARGETED STRATEGIES THROUGH THE NEW YORK STATE SMOKERS QUITLINE (QL) TO HELP NEW YORK STATE’S (NYS) EFFORTS TO ADVANCE HEALTH SYSTEMS CESSATION INTERVENTIONS: OUTCOMES FROM THREE COMMUNICATION STRATEGIES  
Presenter changed to Cheryl Rivard

**LATE BREAKING: HEALTH EQUITY II, POD39-006:** PHYSICAL PAIN, SOCIO-DEMOGRAPHICS, AND PSYCHOLOGICAL CHARACTERISTICS OF CURRENT, FORMER, AND NEVER SMOKERS IN WAVE 4 PATH PARTICIPANTS: A BAYESIAN NETWORK ANALYSIS  
Presenter changed to Marcel de Dios

**RAPID RESPONSE POSTERS, RR-079:** EFFECTS OF ADVERTISING FEATURES ON SMOKER AND NON-SMOKER PERCEPTIONS OF A REDUCED NICOTINE CIGARETTE MODIFIED RISK TOBACCO PRODUCT  
Presenter changed to Andrew Strasser

**RAPID RESPONSE POSTERS, RR-001:** POTENTIAL FACTORS AFFECTING FREE BASE NICOTINE IN E-CIGARETTE AEROSOL  
Presenter changed to Adam Pearcy

**RAPID RESPONSE POSTERS, RR-130:** E-CIGARETTE PREVALENCE, MOTIVATIONS FOR USE, AND RELATIONSHIP WITH TOBACCO IN TEENS - THE CHANGING SITUATION IN IRELAND  
Presenter changed to Salome Sunday

**SMOKING, VAPING AND PLACE, POD33-001:** BAR ATMOSPHERICS AND SMOKING: A QUALITATIVE ANALYSIS OF YOUNG ADULT SMOKERS  
Presenter changed to Janet Hoek

Bekir Kaplan1, Panagis Galiatsatos2, Joanna E. Cohen1. 1Institute for Global Tobacco Control, Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Tobacco Treatment Clinic, Division of Pulmonary & Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Significance: Prior studies investigating the role of electronic nicotine delivery system (ENDS) use in cigarette cessation have largely relied on the analysis of non-representative samples. The aim of this study is to compare the cessation success rate of electronic nicotine delivery system (ENDS), nicotine replacement therapy (NRT), or medication as a cessation aid among Wave 3 cigarette only users who used these methods between Wave 3 and 4. Method: We used the Population Assessment of Tobacco and Health (PATH) Study Wave 3 and 4 adult data. We compared cigarette cessation rate of Wave 3 established cigarette only users who used ENDS, NRT, or medication (varenicline and bupropion) to quit smoking between wave 3 and 4. “Cessation” was defined as being a former cigarette smoker in Wave 4. A chi square test was used to assess the difference in cessation rate across aids. Result: Among 6,794 established cigarette only users in Wave 3, 532 used ENDS, NRT, or medication to quit smoking between Wave 3 and 4: 75 used ENDS only, 289 NRT only, 68 medication only, and 100 used a combination of NRT and medication. Overall, 16.1% (n=86) became former smokers. Among those who used ENDS only to quit, 16.2% (n=14) became former smokers. The same percentages were: 16.1% (n=47) for NRT, 17.7% (n=13) for medication, and 14.8% (n=12) for a combination of both NRT and medication (p=0.97). In total, 192 cigarette only users in Wave 3 used ENDS to quit smoking with or without other methods and none of them became ENDS only users in Wave 4, 37.6% (n=71) of them became dual users of both cigarette and ENDS, 52.8% (n=100) remained as cigarette only users, and 9.6% (n=21) became nonusers of any tobacco product in Wave 4. Conclusion: Using data from this nationally representative study, we found no difference in cessation rates for using ENDS only, NRT only, or non-NRT medication only. Cigarette smokers should be encouraged to use FDA approved cessation methods to quit cigarette smoking to reduce health risks associated with dual use of cigarette and ENDS. FUNDING: Federal

FEATURED CLINICAL POSTERS, POD53-007: EFFECTS OF SHORT-TERM NICOTINE DEPRIVATION ON DELAY DISCOUNTING AMONG YOUNG E-CIGARETTE USERS.
Poster erroneously listed in this session. Correct session is POD14-002